Next, we investigated whether CD11b+Ly6G−Ly6C− MDCs depletion could enhance the efficacy of the current standard glioma chemotherapeutic agent Temozolamide (TMZ) [5]. This evidence concerns the gene ITGAM and central nervous system cancer.